INVESTMENTS (Tables)

3 Months Ended

Oct. 31, 2023

Investments, Debt and Equity Securities [Abstract]

The following table summarizes the Company's investments as of October 31, 2023. There were no investments as of July 31, 2023.


	Successor
	October 31, 2023
Convertible loan note investment(a)	$	1,227
Other investments(b)	2,216
Total	$	3,443

(a) The Company entered into a new convertible loan note on October 13, 2023, which matures on March 31, 2025. The Company paid 1.0 million GBP (approximately $1.2 million) to subscribe for an amount of £1.0 million (the "loan principal") of 11.0% 2025 unsecured convertible loan notes issued by the investee (the "CLN Instrument Agreement"). Contemporaneous with the execution of the CLN Instrument Agreement, the Company executed the Equity Warrant Instrument Agreement (“Warrant Agreement”), which provides the Company with the option to convert the outstanding balance into equity shares of the investee at any time before repayment of the outstanding loan principal balance. The Company’s £1.0 million investment in the £20.0 million GBP 11.0% unsecured convertible loan notes provides it with an approximate 5.0% ownership interest on an if-converted basis. The cost basis of the convertible loan note investment was $1.2 million as of October 31, 2023, which also approximates its fair value. Changes in fair value will be recorded in the Company's consolidated statements of operations as the Company elected the fair value option under ASC 825 to account for this investment.

(b) The balance consists of multiple common stock investments of public companies. All were accounted for under ASC 321.

Unrealized Gain (Loss) on Investments

The amount of net unrealized losses for the three months ended October 31, 2023 that relate to equity securities still held as of October 31, 2023 are as follows:


	Successor
	Three months ended October 31,
	2023
Unrealized losses recognized during the period on equity securities still held at the end of the period	$	447